UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008887
Receipt number R000010426
Scientific Title Randomized control study to evaluate the efficacy of adjuvant androgen deprivation therapy after rotational IMRT in patients with high risk prostate cancer
Date of disclosure of the study information 2012/09/10
Last modified on 2021/03/17 09:35:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized control study to evaluate the efficacy of adjuvant androgen deprivation therapy after rotational IMRT in patients with high risk prostate cancer

Acronym

Randomized control study to evaluate the efficacy of adjuvant androgen deprivation therapy after rotational IMRT in patients with high risk prostate cancer

Scientific Title

Randomized control study to evaluate the efficacy of adjuvant androgen deprivation therapy after rotational IMRT in patients with high risk prostate cancer

Scientific Title:Acronym

Randomized control study to evaluate the efficacy of adjuvant androgen deprivation therapy after rotational IMRT in patients with high risk prostate cancer

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of long-term adjuvant androgen deprivation therapy to 76 Gy external beam radiation therapy with rotational IMRT in patients with high-risk prostate cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

PSA-progression free survival

Key secondary outcomes

Overall survival
Cause-specific survival
QOL
Adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Patients receive Combined Androgen Blockade (CAB) with LH-RH agonist and anti-androgen for 4 months as neoadjuvant hormonal therapy. After that, patients receive 76Gy external beam radiotherapy (EBRT) with Rotational IMRT for about 2 months (CAB is continued during radiotherapy period but no further hormonal treatment after EBRT).

Interventions/Control_2

Patients receive Combined Androgen Blockade (CAB) with LH-RH agonist and anti-androgen for 4 months as neo-adjuvant hormonal therapy. After that, patients receive 76Gy external beam radiotherapy (EBRT) with Rotational IMRT for about 2 months (CAB is continued during radiotherapy period and only LH-RH agonist is continued for 24 months as adjuvant hormonal therapy after EBRT).

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

79 years-old >=

Gender

Male

Key inclusion criteria

1.High risk prostate cancer patient
(by NCCN recurrence risk)
2.Performance status 0-1 (ECOG)
3.Age: 40-79 years old
4.Patients who satisfy the following
(1)WBC>=3.0x103/microL
(2)hemoglobin>=10.0 g/dL
(3) platelet>=10x104/microL
(4)erum creatinine<=2.0 mg/dL
(5)AST<=100 IU/L
(6)ALT<=100 IU/L
5.Written informed consent

Key exclusion criteria

1.Clinical stage T3b or T4
2.Patients who has metastasis with lymph node or distant lesion
3.Patients with active another cancer
4.Patients with uncontrollable hypertension
5.Patients with severe psychiatric disorders
6.Patients with connective tissue disease
7.Patients with poorly controlled diabetes
8.Patients with poorly controlled ischemic heart disease
9.Patients who had prior surgery for prostate (e.g. radical prostatectomy)
10.Patients who had prior radiotherapy (e.g. EBRT, brachytherapy)
11.Patients who had prior orchiectomy
12.Patients who are treated with steroids (except for external use for skin)
13.Patients who are treated with anti-androgen for BPH
14.Patients who considered inappropriate for this trial by physicians

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Taketo
Middle name
Last name Kawai

Organization

The University of Tokyo Hospital

Division name

Department of Urology

Zip code

113-8655

Address

7-3-1, Hongo, Bunkyo-ku, Tokyo

TEL

03-3815-5411

Email

kawait-uro@h.u-tokyo.ac.jp


Public contact

Name of contact person

1st name Shiraishi
Middle name
Last name Kenshiro

Organization

The University of Tokyo Hospital

Division name

Department of Radiology

Zip code

113-8655

Address

7-3-1, Hongo, Bunkyo-ku, Tokyo

TEL

03-3815-5411

Homepage URL


Email

kshiraishi-tky@umin.ac.jp


Sponsor or person

Institute

The University of Tokyo Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical Research Support Center at The University of Tokyo Hospital

Address

7-3-1, Hongo, Bunkyo-ku, Tokyo

Tel

03-3815-5411

Email

crctky-office@umin.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京大学医学部附属病院(東京都)
社会福祉法人 仁生会 江戸川病院(東京都)


Other administrative information

Date of disclosure of the study information

2012 Year 09 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2011 Year 10 Month 17 Day

Date of IRB


Anticipated trial start date

2012 Year 09 Month 17 Day

Last follow-up date

2021 Year 12 Month 23 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 09 Month 10 Day

Last modified on

2021 Year 03 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010426


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name